Clinical Trials Directory

Trials / Unknown

UnknownNCT02239952

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Pilot Study on the Determination of Tumor Concentrations of Protein Kinase Inhibitors in Patients With Newly Diagnosed High-grade Glioma

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
15 (estimated)
Sponsor
Amsterdam UMC, location VUmc · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue (in the brain) of patients with high-grade gliomas (HGG).

Detailed description

In clinical trials for HGG, multiple agents targeting various oncogenic signaling pathways that play an important role in the biology of HGG have been studied, but unfortunately only a small number of patients seem to benefit from these treatment strategies. Whether these disappointing results are due to a restricted drug delivery through the blood-brain barrier, or due to differential biological characteristics of these HGGs, remains unknown. To better understand these clinical observations and to find potential insight how to overcome them, we intend to measure tumor concentrations of PKIs after approximately two weeks treatment and to determine whether these tumor concentrations correlate with plasma- and CSF concentrations of PKIs. Subsequently, we intend to determine the (phospho)proteomic profiles and kinase inhibitory activity in tumor tissue from these HGG patients after approximately two weeks of treatment with a PKI.

Conditions

Interventions

TypeNameDescription
DRUGSunitinib50 mg once daily, oral use for 14 days
DRUGvandetanib300 mg, once daily, oral use for 14 days
DRUGErlotinib150 mg, once daily, oral use for 14 days

Timeline

Start date
2014-11-01
Primary completion
2021-11-01
Completion
2021-11-01
First posted
2014-09-15
Last updated
2020-10-08

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02239952. Inclusion in this directory is not an endorsement.